499 related articles for article (PubMed ID: 20514403)
1. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer.
Liang G; Tang A; Lin X; Li L; Zhang S; Huang Z; Tang H; Li QQ
Int J Oncol; 2010 Jul; 37(1):111-23. PubMed ID: 20514403
[TBL] [Abstract][Full Text] [Related]
2. Reversal of cancer multidrug resistance by green tea polyphenols.
Mei Y; Qian F; Wei D; Liu J
J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
[TBL] [Abstract][Full Text] [Related]
3. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
Jin J; Wang FP; Wei H; Liu G
Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
[TBL] [Abstract][Full Text] [Related]
4. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells.
Jung YD; Kim MS; Shin BA; Chay KO; Ahn BW; Liu W; Bucana CD; Gallick GE; Ellis LM
Br J Cancer; 2001 Mar; 84(6):844-50. PubMed ID: 11259102
[TBL] [Abstract][Full Text] [Related]
5. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
6. In vivo reversal of doxorubicin resistance by (-)-epigallocatechin gallate in a solid human carcinoma xenograft.
Zhang Q; Wei D; Liu J
Cancer Lett; 2004 May; 208(2):179-86. PubMed ID: 15142676
[TBL] [Abstract][Full Text] [Related]
7. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells.
Qian F; Wei D; Zhang Q; Yang S
Biomed Pharmacother; 2005 Apr; 59(3):64-9. PubMed ID: 15795098
[TBL] [Abstract][Full Text] [Related]
8. Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo.
Thangapazham RL; Singh AK; Sharma A; Warren J; Gaddipati JP; Maheshwari RK
Cancer Lett; 2007 Jan; 245(1-2):232-41. PubMed ID: 16519995
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells.
Kitagawa S; Nabekura T; Kamiyama S
J Pharm Pharmacol; 2004 Aug; 56(8):1001-5. PubMed ID: 15285844
[TBL] [Abstract][Full Text] [Related]
10. Autophagy inhibition contributes to the synergistic interaction between EGCG and doxorubicin to kill the hepatoma Hep3B cells.
Chen L; Ye HL; Zhang G; Yao WM; Chen XZ; Zhang FC; Liang G
PLoS One; 2014; 9(1):e85771. PubMed ID: 24465696
[TBL] [Abstract][Full Text] [Related]
11. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
Ramachandran C; Wellham LL
Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
[TBL] [Abstract][Full Text] [Related]
12. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate.
Fassina G; Venè R; Morini M; Minghelli S; Benelli R; Noonan DM; Albini A
Clin Cancer Res; 2004 Jul; 10(14):4865-73. PubMed ID: 15269163
[TBL] [Abstract][Full Text] [Related]
14. High-dose acetaminophen inhibits the lethal effect of doxorubicin in HepG2 cells: the role of P-glycoprotein and mitogen-activated protein kinase p44/42 pathway.
Manov I; Bashenko Y; Eliaz-Wolkowicz A; Mizrahi M; Liran O; Iancu TC
J Pharmacol Exp Ther; 2007 Sep; 322(3):1013-22. PubMed ID: 17526808
[TBL] [Abstract][Full Text] [Related]
15. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.
Nishikawa T; Nakajima T; Moriguchi M; Jo M; Sekoguchi S; Ishii M; Takashima H; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
J Hepatol; 2006 Jun; 44(6):1074-82. PubMed ID: 16481065
[TBL] [Abstract][Full Text] [Related]
16. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of lung resistance related protein by RNA interference targeting survivin induces the reversal of chemoresistances in hepatocellular carcinoma.
Song X; Wang JB; Yin DL; Yang HY; Liu LX; Jiang HC
Chin Med J (Engl); 2009 Nov; 122(21):2636-42. PubMed ID: 19951584
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
19. [MDR-reversing effect of two components of catechin on human hepatocellular carcinoma BEL-7404/Adr in vitro].
Liang G; Zhang S; Huang ZM; Tang AZ
Ai Zheng; 2004 Apr; 23(4):401-5. PubMed ID: 15087027
[TBL] [Abstract][Full Text] [Related]
20. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
